Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 17,105 matching trials from the live ClinicalTrials.gov search.

Filters: Philadelphia, Pennsylvania Clear all

Conditions: Acute Lymphoblastic Leukemia (ALL)
Interventions: Carfilzomib, Dexamethasone, Mitoxantrone, PEG-asparaginase, Vincristine, Intrathecal (IT) Methotrexate, Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate), 6-Mercaptopurine, Cyclophosphamide, Cytarabine, Daunorubicin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 1 Month to 21 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 22
States / cities: Oakland, California • Orange, California • Aurora, Colorado + 19 more

Conditions: Aphasia
Interventions: Repetitive Transcranial Magnetic Stimulation, Sham TMS; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Disturbances in Initiating and Maintaining Sleep, Behavior Problem
Interventions: Omega-3 fatty acids, Placebo; Dietary Supplement
Lead sponsor: University of Pennsylvania; Other
Eligibility: 5 Years to 9 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Advance Care Planning, Chronic Kidney Diseases, Conservative Kidney Management
Interventions: ESRD education + conservative kidney management and ACP education; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 65 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Major Depressive Disorder With Mixed Features
Interventions: Lurasidone, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 19
States / cities: Birmingham, Alabama • Escondido, California • Garden Grove, California + 15 more

Conditions: Coronary Disease, Diabetes Mellitus
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 15,067 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 95
States / cities: Alabaster, Alabama • Birmingham, Alabama • Gilbert, Arizona + 92 more

Conditions: Pediatric Neoplasm, Quality of Life, Outcome Assessment, Palliative Care
Interventions: Routine Data collection, Feedback of patient-reported outcomes; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 2 Years to 25 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 4
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Cognition - Other
Interventions: Inguinal hernia surgery, General anesthesia; Procedure
Lead sponsor: Columbia University; Other
Eligibility: 8 Years to 15 Years
Enrollment: 369 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Neonatal Opioid Withdrawal Syndrome
Interventions: Not listed
Lead sponsor: Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program; Network
Eligibility: Up to 1 Month
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 6
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Durham, North Carolina + 3 more

Conditions: Smoldering Multiple Myeloma
Interventions: IPH2101; Drug
Lead sponsor: Innate Pharma; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Columbus, Ohio + 2 more

Conditions: Hypothermia Following Anesthesia, Hypothermia, Surgery
Interventions: EnsoETM, Surface Warming; Device
Lead sponsor: Advanced Cooling Therapy, Inc., d/b/a Attune Medical; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Kidney Disease (CKD)
Interventions: Epoetin Hospira Arm, Standard of Care Arm, IV Iron; Biological · Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 42
States / cities: Chula Vista, California • Poway, California • Rancho Bernardo, California + 24 more

Conditions: Episodic Migraine Headache
Interventions: LBR-101 High Dose, LBR-101 Low Dose, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 63
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 56 more

Conditions: Spinal Muscular Atrophy
Interventions: Onasemnogene Abeparvovec-xioi; Biological
Lead sponsor: Novartis Gene Therapies; Industry
Eligibility: 6 Months to 60 Months
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 11
States / cities: Los Angeles, California • Stanford, California • Orlando, Florida + 8 more

Conditions: Asthma
Interventions: Aerovant, placebo; Drug · Other
Lead sponsor: Aerovance, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 38
States / cities: Mobile, Alabama • Scottsdale, Arizona • Huntington Beach, California + 31 more

Conditions: Schizophrenia
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 2,025 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 7
States / cities: Los Angeles, California • San Diego, California • Denver, Colorado + 4 more

Conditions: Rhabdoid Tumors, INI1-negative Tumors, Synovial Sarcoma, Malignant Rhabdoid Tumor of Ovary
Interventions: Tazemetostat; Drug
Lead sponsor: Epizyme, Inc.; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 13 more

Conditions: Polycystic Ovary Syndrome
Interventions: Elagolix, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 50
States / cities: Birmingham, Alabama • Mobile, Alabama • San Diego, California + 43 more

Conditions: GM1 Gangliosidosis, GM1 Gangliosidosis, Type I, GM1 Gangliosidosis, Type 2, Beta-Galactosidase-1 (GLB1) Deficiency
Interventions: PBGM01; Biological
Lead sponsor: Gemma Biotherapeutics; Industry
Eligibility: 1 Month to 24 Months
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 4
States / cities: Oakland, California • Minneapolis, Minnesota • New Brunswick, New Jersey + 1 more

Conditions: Pulmonary Hypertension of Newborn
Interventions: INOmax; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 27 Weeks to 40 Weeks
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 30
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more

Conditions: Pompe Disease
Interventions: ATB200, AT2221; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 12
States / cities: Phoenix, Arizona • Orange, California • Gainesville, Florida + 9 more

Conditions: Aortic Valve Stenosis
Interventions: TAVR with CENTERA THV; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: Not listed
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 23
States / cities: Los Angeles, California • Stanford, California • Loveland, Colorado + 19 more

Conditions: Mobile Application-Based CBT Worksheet Collection, Paper-Based Worksheet Collection
Interventions: Cognitive Behavioral Therapy; Behavioral
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 4
States / cities: Palo Alto, California • Boston, Massachusetts • Chelsea, Massachusetts + 1 more

Conditions: Hypertension
Interventions: Opt-In Recruitment, Opt-Out Recruitment; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

TMS in Aphasia Recovery

Effect of Omega-3 Fatty Acids on Sleep and Behavior (Pilot Study)

Integrating Conservative Kidney Management Options and Advance Care Planning Into a Pre-Dialysis Educational Program

Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose

A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease

The PediQUEST Study: Evaluation of Pediatric Quality of Life and Evaluation of Symptoms Technology

PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study

ACT NOW Longitudinal Study: Outcomes of Babies With Opioid Exposure Study

Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma

Intraoperative Warming During Major Surgical Procedures Using the Esophageal Temperature Management System

A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine

Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy

A Study of the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients, AEROTRIAL

The Genetic Basis of Inherited Neurologic Deficits in People With Schizophrenia

EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome

Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis

Registry to Evaluate INOmax in Newborn Babies With Pulmonary Hypertension

First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis

Innovative Methods to Assess Psychotherapy Practices (imAPP)

SupportBP 2.0:Behavioral Science and Enrollment in Remote Monitoring for Hypertension Management